Estimating the benefit and cost of radiotherapy for lung cancer

International Journal of Technology Assessment in Health Care

Volumn 20, Issue 4, 2004, Pages 545-551

  Barbera, Lisa ^a,e   Walker, Hugh ^b   Foroudi, Farshad ^c   Tyldesley, Scott ^d   Mackillop, William ^b  

^a DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

^b QUEEN S UNIVERSITY   (Canada)

^c PETER MACCALLUM CANCER CENTRE   (Australia)

^d BRITISH COLUMBIA CANCER AGENCY   (Canada)

^e Institut national du cancer du Canada   (Canada)

Author keywords

Costs and cost analysis; Lung neoplasms; Radiotherapy

Indexed keywords

CARDIOLOGY; CLINICAL LABORATORIES; COST EFFECTIVENESS; DIAGNOSIS; DISEASES; HEALTH CARE; PATIENT MONITORING; PUBLIC POLICY; RADIOTHERAPY;

DISEASE SYMPTOMS; EPIDEMICS; LUNG CANCER; SYMPTOMS CONTROL;

TUMORS;

CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER REGISTRY; CANCER SURVIVAL; COST BENEFIT ANALYSIS; HEALTH CARE COST; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; QUALITY ADJUSTED LIFE YEAR; REVIEW; SENSITIVITY ANALYSIS; TREATMENT INDICATION;

EID: 8544273300     PISSN: 02664623     EISSN: None     Source Type: Journal    
DOI: 10.1017/S0266462304001485     Document Type: Review

References (43)

1. American College of Radiology Task Force on Appropriateness Criteria. Appropriateness criteria for imaging and treatment decisions in radiation oncology. Reston, VA: American College of Radiology; 1996.
2. Auperin A, Arriagada R, Pignon JP, et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. N Engl J Med. 1999;341:476-484.
3. Barton MB, Gebski V, Manderson C, Langlands AO. Radiation therapy: Are we getting value for money? Clin Oncol (R Coll Radiol). 1995;7:287-292.
4. BC Cancer Agency. Cancer Management Guidelines. Cancer Management Manual. 2001. Available at: www.bccancer.bc.ca
5. Borgelt B, Gelber R, Kramer S, et al. The palliation of brain metastases: Final results of the first two studies by the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys. 1980;6:1-9.
6. Byhardt RW, Scott C, Sause WT, et al. Response, toxicity, failure patterns, and survival in five Radiation Therapy Oncology Group (RTOG) trials of sequential and/or concurrent chemotherapy and radiotherapy for locally advanced non-small-cell carcinoma of the lung. Int J Radiat Oncol Biol Phys. 1998;42:469-478.
7. Carmichael J, Crane JM, Bunn PA, Glatstein E, Ihde DC. Results of therapeutic cranial irradiation in small cell lung cancer. Int J Radiat Oncol Biol Phys. 1988;14:455-459.
8. Chapman RH, Stone PW, Sandberg EA, Bell C, Neumann PJ. A comprehensive league table of cost-utility ratios and a sub-table of "panel-worthy" studies. Med Decis Making. 2000;20:451-467.
9. Computing in Humanities and Social Sciences Facility. Cansim Database. CansimII@chass. 2002. Available at: http://datacenter2.chass.utoronto.ca/cansim/ cansim.html
10. Coulter A, Ham C. The global challenge of health care rationing. Buckingham: Open University Press; 2002.
11. Coy P, Schaafsma J, Schofield JA. The cost-effectiveness and cost-utility of high-dose palliative radiotherapy for advanced non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2000;48:1025-1033.
12. Dillman RO, Seagren SL, Propert KJ, et al. A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. N Engl J Med. 1990;323:940-945.
13. Dunscombe P, Roberts G, Walker J. The cost of radiotherapy as a function of facility size and hours of operation. Br J Radiol. 1999;72:598-603.
14. Durrant KR, Berry RJ, Ellis F, et al. Comparison of treatment policies in inoperable bronchial carcinoma. Lancet. 1971:1:715-719.
15. Earle C, Coyle D, Smith A, Agboola O, Evans WK. The cost of radiotherapy at an Ontario regional cancer centre: A re-evaluation. Crit Rev Oncol-Hematol. 1999;32:87-93.
16. Earle CC, Chapman RH, Baker CS, et al. Systematic overview of cost-utility assessments in oncology. J Clin Oncol. 2000;18:3302-3317.
17. Ettinger DS, Cox JD, Ginsberg RJ, et al. NCCN Non-Small-Cell Lung Cancer Practice Guidelines. The National Comprehensive Cancer Network. Oncology (Huntingt). 1996;10:81-111.
18. Evans WK, Will BP, Berthelot JM, Earle CC. Cost of combined modality interventions for stage III non-small-cell lung cancer [see comments]. J Clin Oncol. 1997;15:3038-3048.
19. Evans WK, Will BP, Berthelot JM, Wolfson MC. Diagnostic and therapeutic approaches to lung cancer in Canada and their costs. Br J Cancer. 1995;72:1270-1277.
20. Evans WK, Will BP, Berthelot JM, Wolfson MC. The economics of lung cancer management in Canada. Lung Cancer. 1996;14:19-29.
21. Glazebrook GA. Radiation therapy: A long term cost benefit analysis in a North American region. Clin Oncol (R Coll Radiol). 1992;4:302-305.
22. Goddard M, Hutton J. Economic evaluation of trends in cancer therapy. Marginal or average costs? Int J Technol Assess Health Care. 1991;7:594-603.
23. Goodwin PJ, Feld R, Evans WK, Pater J. Cost-effectiveness of cancer chemotherapy: An economic evaluation of a randomized trial in small-cell lung cancer. J Clin Oncol. 1988;6:1537-1547.
24. Komaki R, Scott CB, Sause WT, et al. Induction cisplatin/vinblastine and irradiation vs. irradiation in unresectable squamous cell lung cancer: Failure patterns by cell type in RTOG 88-08/ECOG 4588. Radiation Therapy Oncology Group. Eastern Cooperative Oncology Group. Int J Radiat Oncol Biol Phys. 1997:39:537-544.
25. Laupacis A, Feeny D, Detsky AS, Tugwell PX. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. Can Med Assoc J. 1992;146:473-481.
26. Le Chevalier T, Arriagada R, Quoix E, et al. Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer: First analysis of a randomized trial in 353 patients. J Natl Cancer Inst. 1991; 83:417-423.
27. Mathers CD, Boschi-Pinto C, Lopez AD, Murray CJ. Cancer incidence, mortality and survival by site for 14 different regions of the world. (Discussion Paper 13) In: Global programme on evidence for health policy. Geneva: World Health Organization; 2001.
28. Medical Research Council. Inoperable non-small-cell lung cancer (NSCLC): A Medical Research Council randomised trial of palliative radiotherapy with two fractions or ten fractions. Report to the Medical Research Council by its Lung Cancer Working Party. Br J Cancer. 1991;63:265-270.
29. National Cancer Institute, CancerNet: A service of the National Cancer Institute. PDQ Cancer Information Summaries: Treatment. Monograph on-line. 2002. Available at: http://cancernet.nci.nih.gov/pdq/pdq-treatment.shtml
30. Pignon JP, Arriagada R, Ihde DC, et al. A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med. 1992;327:1618-1624.
31. PORT Meta-analysis Trialists Group. Postoperative radiotherapy in non-small-cell lung cancer: Systematic review and meta-analysis of individual patient data from nine randomised controlled trials. PORT Meta-analysis Trialists Group. Lancet. 1998;352:257-263.
32. Pritchard RS, Anthony SP. Chemotherapy plus radiotherapy compared with radiotherapy alone in the treatment of locally advanced, unresectable, non-small-cell lung cancer. A meta-analysis. Ann Intern Med. 1996;125:723-729.
33. Roswit B, Patno ME, Rapp R, et al. The survival of patients with inoperable lung cancer: A large-scale randomized study of radiation therapy versus placebo. Radiology. 1968;90:688-697.
34. Sackett DL. Rules of evidence and clinical recommendations on the use of antithrombotic agents. Chest. 1989;95:2S-4S.
35. Schaafsma J, Coy P. The effect of radiotherapy on the survival of non-small cell lung cancer patients. Int J Radiat Oncol Biol Phys. 1998;41:291-298.
36. Schaafsma J, Coy P. Response of global quality of life to high-dose palliative radiotherapy for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2000;47:691-701.
37. Schaake-Koning C, van den Bogaert W, Dalesio O, et al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med. 1992;326:524-530.
38. Scottish Intercollegiate Guidelines Network. Management of Lung Cancer. Monograph on-line. 1998. Available at: www.show.scot.nhs.uk/sign/html/htmtxt23. htm
39. Stephens RJ, Girling DJ, Bleehen NM, et al. The role of post-operative radiotherapy in non-small-cell lung cancer: A multicentre randomised trial in patients with pathologically staged T1-2, N1-2, M0 disease. Medical Research Council Lung Cancer Working Party. Br J Cancer. 1996;74:632-639.
40. Stevens G, Firth I. Audit in radiation therapy: Long-term survival and cost of treatment. Australas Radiol. 1997;41:29-34.
41. Tong D, Gillick L, Hendrickson FR. The palliation of symptomatic osseous metastases: Final results of the study by the Radiation Therapy Oncology Group. Cancer. 1982;50:893-899.
42. Tyldesley S, Boyd CJ, Schulze K, Walker H, Mackillop WJ. Estimating the need for radiotherapy for lung cancer: An evidence based, epidemiological approach. Int J Radiat Oncol Biol Phys. 2001;49:973-985.
43. Wodinsky HB, Jenkin RD. The cost of radiation treatment at an Ontario regional cancer centre. CMAJ. 1987;137:906-909.